Triple Oral Lipid‑Lowering Therapy Including Bempedoic Acid Versus Usual Care in Early Management of Acute Coronary Syndrome Patients

The trial enrolled individuals diagnosed with Acute Coronary Syndrome, encompassing both female and male patients. Age eligibility was defined by the study’s internal coding system, but specific age limits were not disclosed. The sponsor did not provide the total number of participants. Subjects were selected on the basis of having the target diagnosis and being classified as patients, without additional information on lifestyle factors such as diet, physical activity, or habits. No further inclusion or exclusion criteria were detailed in the provided data.

The study titled “Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with Acute Coronary Syndrome” is a phase 5 clinical trial scheduled to run from September 14 2026 to September 12 2027. Eligible participants will first attend a screening visit to confirm inclusion criteria and obtain baseline assessments. Following enrollment, subjects will be assigned to receive either the investigational triple oral regimen or standard care and will return for scheduled follow‑up visits at regular intervals to monitor efficacy, safety, and adherence. The final visit, designated as the end‑of‑study assessment, will occur at the conclusion of the trial period, resulting in an overall participant involvement of approximately twelve months. Early termination of individual participation may be implemented if predefined safety or compliance criteria are met.

Efficacy will be evaluated in accordance with the predefined study protocol for participants diagnosed with Acute Coronary Syndrome.